OPEN APP
Home / Companies / News /  Zydus Cadila starts human dosing of covid-19 vaccine candidate

NEW DELHI: Zydus Cadila Ltd has started human dosing of its covid-19 vaccine candidate as part of its phase I and II trial to test for its safety and immunogencity of the vaccine.

“We look forward to the adaptive phase I/II clinical studies and gathering important data on ZyCoV-D in the months ahead," Zydus Cadila chairman Pankaj R. Patel said in a statement.

The company is conducting its trial at its Zydus Research Centre in Moraiya near Ahmedabad.

The Ahmedabad-based company had earlier this month received an approval from the Drug Controller General of India V.G. Somani to conduct a phase I/II trial on 1,048 participants. The entire trial is expected to complete in one year, as per the government’s clinical trial registry.

The 1,048 healthy participants will be divided into two groups, with the first being given the vaccine candidate and the second a placebo. Placebo is a substance with no therapeutic effect that is used only to act as a control arm of the trial against which the vaccine candidate will be compared.

As part of the trial, three doses of the vaccine will be given to the participants, with the first dose on day 0, and the subsequent two doses 28 days apart, as per the clinical trial registry.

Zydus Cadila’s vaccine candidate is one of two from India for which human trials have been allowed. The other candidate is the one jointly developed by Bharat Biotech International Ltd and Indian Council of Research’s National Institute of Virology in Pune.

Unlike Zydus’ vaccine candidate, Bharat Biotech’s vaccine has been under considerable limelight since a controversial letter was written by the ICMR director-general Balram Bhargava earlier this month directing the company and the 12 principal investigators at the trial sites to expedite the trial to start enrolment by 7 July and complete it by 15 August.

However, enrolment of patients in Bharat Biotech’s trial only started on Monday, as per the clinical trial registry. Bharat Biotech plans to conduct the trial with 1,125 participants.

ICMR and the government has since then backtracked on the deadline, only sticking to the stance of expediting it during the pandemic.


Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Close

Recommended For You

×
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout